StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project:[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
  1. Startseite
  2. /Verbindung

Triprolidin

Triprolidine

HCID 5282443
NotizenReaktionen
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
486-12-4
Standard-SMILES
Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
InChIKey
CBEQULMOCCWAQT-WOJGMQOQSA-N
Summenformel
C19H22N2
Durchschnittliche Molmasse
278,4 g/mol
Monoisotopische Masse
278,1782987

Überblick

Triprolidine is an N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders. It has a role as a H1-receptor antagonist. It is a member of pyridines, a N-alkylpyrrolidine and an olefinic compound. It is a conjugate base of a triprolidine(1+).

Namen und Bezeichner

Bevorzugter Name
Triprolidine
IUPAC
2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine
Lokaler Name
Triprolidin
Englischer Name
Triprolidine
Summenformel
C19H22N2
Molmasse
278.39

Namen und Synonyme

triprolidine486-12-4TriprolidinActidilTripolidinaTriprolidinumTriprolidinaDTXSID3023718trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-eneNCI-C614502-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridinetrans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene
Weitere Namen anzeigen
(e)-pyridinTripyrolidineTriprolidine USP/EP/BPTriprolidine (Standard)(E)-1-(2-pyridyl)-3-pyrrolidin-1-yl-1-p-tolylpropene
trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine2L8T9S52QM2-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridineDTXCID203718CHEBI:84116Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, (E)-(E)-2-[3-(1-Pyrrolidinyl)-1-p-toluenepropenyl]pyridine(E)-2-(3-(1-pyrrolidinyl)-1-p-toluenepropenyl)pyridine

Datenbank-Bezeichner

CAS
486-12-4
PubChem CID
5282443

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,9
Polarare Oberfläche (TPSA)
16,1 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
4
Schwere Atome
21
Formalladung
0
Komplexität
335

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 Einträge

4

3.87

Color/FormCrystals from light petroleum
Solubility5.37e-02 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Antihistamines

Pharmaceuticals

Melting Point · 2 Einträge

59-61 °C

60 °C

Physical DescriptionSolid
Dissociation Constants · 2 Einträge

9.69

9.25

Collision Cross Section167.67 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Gefahrenhinweise

Other Safety InformationIMAP assessments - Pyridine, 2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-, (E)-: Environment tier I assessment
FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Sicherheit und Schutzausrüstung

Disposal Methods · 1 Eintrag

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxikologische Informationen

Interactions · 5 Einträge

Concurrent use /of ototoxic medications/ with antihistamines may mask the symptoms of ototoxicity such as tinnitus, dizziness, or vertigo. /Antihistamines/

Concurrent use of monoamine oxidase (MAO) inhibitors with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines; concurrent use is not recommended. /Antihistamines/

Concurrent use /with alcohol or other CNS depression-producing medications/ may potentiate the CNS depressant effects of either these medications or antihistamines; also, concurrent use of maprotiline or tricyclic antidepressants may potentiate the anticholinergic effects of either antihistamines or these medications. /Antihistamines/

Anticholinergic effects may be potentiated when /anticholinergics or other medications with anticholinergic activity/ are used concurrently with antihistamines; patients should be advised to report occurrence of gastrointestinal problems promptly since paralytic ileus may occur with concurrent therapy. /Antihistamines/

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

R - Respiratory system

QR - Respiratory system

Pharmacodynamics · 1 Eintrag

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Triprolidine, is a histamine H1 antagonist that competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Triprolidine has anticholinergic and sedative effects.

Mechanism of Action · 6 Einträge

Triprolidine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

Antihistamines used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. They thereby prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus. Also, the anticholinergic actions of most antihistamines provide a drying effect on the nasal mucosa. /Antihistamines/

Antihistamines used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. They thereby prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus. Also, the anticholinergic actions of most antihistamines provide a drying effect on the nasal mucosa. /Antihistamines/

H1 antagonists inhibit most responses of smooth muscle to histamine. Antagonism of the constrictor action of histamine on respiratory smooth muscle is easily shown in vivo and in vitro. /Histamine Antagonists: H1 Antagonists/

Zugehörige Reaktionen

7
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1803087
HRID 1803087als Produktuspto-grants-2013_01
Reaktionsgleichung von HRID 1803088
HRID 1803088als Eduktuspto-grants-2013_01
Reaktionsgleichung von HRID 1803089
HRID 1803089als Produktuspto-grants-2013_01
Reaktionsgleichung von HRID 1803090
HRID 1803090als Eduktuspto-grants-2013_01
Reaktionsgleichung von HRID 1803091
HRID 1803091als Produktuspto-grants-2013_01
Reaktionsgleichung von HRID 1803092
HRID 1803092als Eduktuspto-grants-2013_01
Reaktionsgleichung von HRID 2250421
HRID 2250421als Produktuspto-grants-2008_01

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
DTXSID
DTXSID3023718
ChEMBL
CHEMBL855
ChEBI
CHEBI:84116
UNII
2L8T9S52QM
EC Number
207-627-0
Nikkaji
J6.005D

Physikochemische Eigenschaften

Schmelzpunkt
59 · 59-61°
Siedepunkt
435.4 · 435.4±34.0 °C(Predicted)
Dichte
1.061 · 1.061±0.06 g/cm3(Predicted)
pka
4.01 · pKa 4.01(H2O t = 23.0) (Uncertain);9.69(H2O t = 23.0) (Uncertain)
CAS Datenbank
486 · 486-12-4(CAS DataBase Reference)
NIST chemische Informationen
Triprolidine(486-12-4)

For more Interactions (Complete) data for TRIPROLIDINE (10 total), please visit the HSDB record page.

HepatotoxicityLike most first generation antihistamines, triprolidine has not been linked to liver test abnormalities or to clinically apparent liver injury. The reason for its safety may relate its use in low dose for short periods only.
Ongoing Test Status · 1 Eintrag

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=486-12-4]

Human Toxicity Excerpts · 4 Einträge

In acute poisoning with H1 antagonists, their central excitatory effects constitute the greatest danger. The syndrome includes hallucinations, excitement, ataxia, incoordination, athetosis, and convulsions. Fixed, dilated pupils with a flushed face, together with sinus tachycardia, urinary retention, dry mouth, and fever, lend the syndrome a remarkable similarity to that of atropine poisoning. Terminally, there is deepening coma with cardiorespiratory collapse and death, usuallY within 2 to 18 hours. Treatment is along general symptomatic and supportive lines. /Histamine Antagonists: H1 Antagonists/

... SIDE EFFECTS INCL DRYNESS OF ... RESP PASSAGES, SOMETIMES INDUCING COUGH; URINARY FREQUENCY & DYSURIA; PALPITATION; HYPOTENSION; HEADACHE; TIGHTNESS OF CHEST; TINGLING, HEAVINESS, & WEAKNESS OF HANDS. ... ALLERGIC DERMATITIS IS NOT UNCOMMON. /ANTIHISTAMINES/

IN SMALL CHILD ... SYNDROME OF POISONING INCL ... ATAXIA, INCOORDINATION, ATHETOSIS ... FIXED, DILATED PUPILS WITH FLUSHED FACE ... ARE COMMON. /ANTIHISTAMINES/

ALTHOUGH H1-BLOCKING DRUGS HAVE RELATIVELY HIGH MARGIN OF SAFETY, ACUTE POISONING WITH THEM IS COMMON. ... IN CHILDREN, 20 TO 30 TABLETS OR CAPSULES OF MOST COMMERCIALLY AVAILABLE ANTIHISTAMINES REPRESENTS LETHAL OR NEAR-LETHAL DOSE. /ANTIHISTAMINES/

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

triprolidine

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 2 Einträge

Externally tested on the eyes of rabbits and found to have a toxicity rating of 5, according to the degree of injury observed after 24 hr. The test is based on a scale of 1-10, with 1 being the least amount of injury.

H1 blockers are among the many drugs that induce hepatic microsomal enzymes, and they may facilitate their own metabolism. /Histamine Antagonists: H1 Antagonists/

Populations at Special Risk · 2 Einträge

Use is not recommended in newborn or premature infants because this age group has an increased susceptibility to anticholinergic side effects, such as central nervous system excitation, and an increased tendency toward convulsions. A paradoxical reaction characterized by hyperexcitability may occur in children taking antihistamines. /Antihistamines/

Dizziness, sedation, confusion, and hypotension may be more likely to occur in geriatric patients taking antihistamines. Geriatric patients are especially susceptible to the anticholinergic side effects, such as dryness of mouth and urinary retention (especially in males), of the antihistamines. If these side effects occur and continue or are severe, medication should probably be discontinued. /Antihistamines/

Antidote and Emergency Treatment · 1 Eintrag

THERE IS NO SPECIFIC THERAPY FOR ANTIHISTAMINE POISONING, AND TREATMENT IS ALONG GENERAL SYMPTOMATIC AND SUPPORTIVE LINES. ... SHOULD BREATHING FAIL, MECH SUPPORT OF VENTILATION OFFER SAFER AND ... EFFECTIVE MEANS OF MAINTAINING RESP THAN USE OF ANALEPTICS WHICH ARE PRONE TO INITIATE OR INTENSIFY CONVULSIVE PHASE. /ANTIHISTAMINES/

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Regulatorische Informationen

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Sicherheitsdaten

Giftige Stoffe Daten
486-12-4(Hazardous Substances Data)

/SRP:/ The action of histamine results in increased permeability and formation of edema and wheal. H1 antagonists block that action.

For more Mechanism of Action (Complete) data for TRIPROLIDINE (7 total), please visit the HSDB record page.

Biological Half-Life · 2 Einträge

4 to 6 hours.

Elimination: 3 to 3.3 hours

Metabolism/MetabolitesMAIN SITE OF METABOLIC TRANSFORMATION IS LIVER. /ANTIHISTAMINES/
MeSH Pharmacological Classification · 2 Einträge

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

Absorption, Distribution and Excretion · 3 Einträge

Rapidly absorbed in the intestinal tract.

The H1 antagonists are well absorbed from the GI tract. Following oral administration, peak plasma concn are achieved in 2 to 3 hr and effects usually last 4 to 6 hr; however, some of the drugs are much longer acting ... . /Histamine Antagonists: H1 Antagonists/

... H1 antagonists are eliminated more rapidly by children than by adults and more slowly in those with severe liver disease. /Histamine Antagonists: H1 Antagonists/

Cellular LocationsExtracellular
Metabolite PathwaysTriprolidine H1-Antihistamine Action

Verwendung und Herstellung

Uses · 2 Einträge

MEDICATION

Use (kg; approx.) in Germany (2009): >25

U.S. Production(1985) 9.57X10+7 g /Antihistamines including triprolidine hydrochloride/
Methods of ManufacturingA commercial reaction is that of 2-pyrridyllithium with the appropriate Mannich ketone to give alcohol which, on dehydration, yields the antihistamine triprolidine
Formulations/PreparationsActidil, Actidilon, Alleract; Pro-actidil, Pro-Entra, Venen 295.C.51. /Triprolidine hydrochloride monohydrate/
Use ClassificationPharmaceuticals
General Manufacturing InformationAdamson, US patents 2,712,020, 2,712,023 (both 1955 to Burroughs Wellcome); Adamson et al, J Chem Soc 1958, 312.

Anwendungen

VerwendenAntihistaminic.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

PyrrolidinLithium ion (1+)4-MethylacetophenonParaformaldehyde2-Brompyridin

Anbieter31 Anbieter

北京华美互利生物化工010-56205725 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
广州佳途科技股份有限公司81960175-877 18933936954 · [email protected]
Dayang Chem (Hangzhou) Co.,Ltd.+86-0571-88938639 17705817739 · [email protected]
浙江珲达生物科技有限公司0571-89903022 18679456698 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
欧利希(湖北)医药科技有限公司17316404525 17316404525 · [email protected]
United Life Science020-82099279 18988968278 · [email protected]
Moxin Chemicals+86-17320513646 +86-17320513646 · [email protected]
TargetMol 中国(陶术生物)400-821-0310 15002144251 · [email protected]
上海阿拉丁生化科技股份有限公司6206333 13167063860 · [email protected]
上海一飞生物科技有限公司021-65675885 18964387627 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
成都标样生物科技有限公司028-81700200 13308200041 · [email protected]
武汉魔力生物科技有限公司18872289958、027-52304252、3400508168 · [email protected]
Shaanxi Didu New Materials Co. Ltd+86-86-17392712779 +86-13289823923 · [email protected]
杭州洁汉化工有限公司+86-571-86217390; +8618058761490 · [email protected]
厦门盈融达化工有限公司+86-0592-6210733 · [email protected]
成都圣美凯生物科技有限公司028-85157043 15882256948 · [email protected]
上海瀚香生物科技有限公司17754423994 · [email protected]
湖北摩科化学有限公司18627753421; 18627756402 · [email protected]
上海杰瑞兴生物医药科技有限公司17521512546 17721492509 · [email protected]
Aladdin Scientific[email protected]
南京艾瑞博生物科技有限公司19951442182 · [email protected]
陕西缔都医药化工有限公司029-029-029-81148696 18161915376 · [email protected]
TargetMol中国(陶术生物)4008200310 15002144251 · [email protected]
上海安谱实验科技股份有限公司18502138905 · [email protected]
重庆卡兰医药有限公司[email protected]
Shaanxi Franta Biotechnology Co., Ltd+86-13082019107 · [email protected]
AFINE CHEMICALS LIMITED+86-571-85134551 +86-18958018566 · [email protected]
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms o uticaria, rhinitis, and various pruritic skin disorders.